L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum

• DOI: 10.1038/srep03730
• Publication Date: 2014-01-16T10:16:18Z
• Authors: Gregory Porras; Philippe De Deurw...; Qin Li; Matteo Marti; Rudolf Morgenstern; Reinhard Sohr; Erwan Bezard; Michele Morari; Wassilios G. Meis...
• Keywords: Male; 0301 basic medicine; Dyskinesias; [SCCO.NEUR]Cognitive science/Neuroscience; Dopamine; Dopamine Agents; Parkinson Disease; Macaca mulatta; Article; Corpus Striatum; Levodopa; Benserazide; Disease Models, Animal; Drug Combinations; 03 medical and health sciences; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Female

L-dopa remains the mainstay treatment for Parkinson's disease (PD), although in later stages, is complicated by L-dopa-induced dyskinesias (LID). Current evidence links LID to excessive striatal L-dopa-derived dopamine (DA) release, while possibility of a direct involvement itself has been largely ignored. Here we show that can alter basal ganglia activity and produce without enhancing DA release parkinsonian non-human primates. These data may have therapeutic implications management advanced PD since they suggest could result from diverse mechanisms action L-dopa.